PHARMENA SA ZY -,1

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2024, PHARMENA SA ZY -,1 has already paid €0.20 in dividends. The last payout was in April 2024.

Financials

In the last quarter, PHARMENA SA ZY -,1 had revenue of €56.29k and net profit of -€231.69k

(EUR)	June 2026	YoY
Revenue	56.29k	38.10%
Gross profit	45.59k	128.59%
Net profit	-231.69k	40.49%
EBITDA	-235.64k	18.23%

Fundamentals

Metric	Value
Market capitalization	€7.1m
Number of shares	11.14m
52-week high/low	€0.98 - €0.57
Dividends	No
Beta	0.51
P/E ratio	-10.06
PEG ratio	0.19
P/B ratio	3.82
P/S ratio	21.35

Company profile

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.